Shri Suggala Ramya, Nayak Yogendra, Ranganath Pai Sreedhara
Department of Pharmacology, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, 576104, India.
F1000Res. 2025 May 27;13:773. doi: 10.12688/f1000research.145391.2. eCollection 2024.
The discovery of an ideal and effective therapy is urgently required for the treatment of Alzheimer's disease (AD). The main pathological hallmarks of Alzheimer's disease that appear before the clinical symptoms are neurofibrillary tangles, amyloid plaques, brain inflammation, and neuronal atrophy throughout the cerebral cortex and hippocampus. GSK-3β (Glycogen Synthase Kinase-3β) is regarded as the most important and promising target for therapeutic use because GSK-3β expression levels increase with age and are the most abundant and hyperactive in the brains of patients with AD. GSK-3β activation or upregulation can contribute to neurodegeneration by promoting amyloid beta (Aβ) production and tau hyperphosphorylation. Whereas the underlying mechanism for abnormal production of GSK-3β in AD brains remains unclear.
Maestro was used, which is Schrodinger, for our computational simulation studies. In the present work, different modules that were used in previous studies with a little modification, the modules such as Protein Preparation with the help of Protein Preparation Wizard, Ligand Preparation with the help of LigPrep, for ADME (Absorption, Distribution, Metabolism and Excretion) prediction Qikprop was used, for docking studies Glide module was used, Binding energy prediction the Prime was used and Molecular dynamic simulation (MDs) studies done using Desmond.
Our focus is mainly on an approach, focusing on library generation; first draw an IMID2 (imidazo [1,5-a]pyridine-3-carboxamide) scaffold structure at Enamine and subjected it to a substructure search to target the receptor grid region (ATP-competitive site) of 6Y9R. They were then subjected to various screening processes. Finally, nine compounds were subjected to MDs studies.
Nine compounds showed good results with the most stable interactions. Among all the MD studies, the compound (Z3336252116) has shown good interaction and a good docking score. Further experiments and studies are required to confirm these results.
治疗阿尔茨海默病(AD)迫切需要发现一种理想且有效的疗法。在临床症状出现之前,阿尔茨海默病的主要病理特征是神经原纤维缠结、淀粉样斑块、脑部炎症以及整个大脑皮层和海马体中的神经元萎缩。糖原合酶激酶 -3β(GSK-3β)被视为治疗用途中最重要且最具潜力的靶点,因为GSK-3β的表达水平随年龄增长而增加,且在AD患者大脑中含量最为丰富且活性过高。GSK-3β的激活或上调可通过促进β淀粉样蛋白(Aβ)生成和tau蛋白过度磷酸化导致神经退行性变。然而,AD大脑中GSK-3β异常产生的潜在机制仍不清楚。
我们使用薛定谔公司的Maestro进行计算模拟研究。在本研究中,对先前研究中使用的不同模块进行了一些修改,这些模块包括借助Protein Preparation Wizard进行蛋白质制备、借助LigPrep进行配体制备,使用Qikprop进行ADME(吸收、分布、代谢和排泄)预测,使用Glide模块进行对接研究,使用Prime进行结合能预测以及使用Desmond进行分子动力学模拟(MDs)研究。
我们主要关注一种方法,重点在于文库生成;首先在Enamine绘制一个IMID2(咪唑并[1,5 - a]吡啶 - 3 - 甲酰胺)支架结构,并对其进行子结构搜索以靶向6Y9R的受体网格区域(ATP竞争位点)。然后对它们进行各种筛选过程。最后,对九种化合物进行了MDs研究。
九种化合物表现出良好的结果,具有最稳定的相互作用。在所有MD研究中,化合物(Z3336252116)表现出良好的相互作用和良好的对接分数。需要进一步的实验和研究来证实这些结果。